Form 4 for INVA Innoviva, Inc.
Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-05 · accession 0001104659-24-032002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-07 | 2024-03-05 | INVA | Ronsheim Matthew | See Remarks | A - Grant | $14.88 | +12.8K | 40.8K | +46% | +$190.0K |
| D | 2024-03-07 | 2024-03-05 | INVA | Ronsheim Matthew | See Remarks | A - Grant | $0.00 | +27.3K | 120.4K | +29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-05 | A | A | 12,768 | $14.88 | 40,778 | D | — | — | (F1) The Reporting Person was granted a one time-based restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2025, 6.25% on May 20, 2025, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company. |
| 2 | Derivative | Non-statutory Stock Option | 2024-03-05 | A | A | 27,338 | $0.00 | 120,438 | D | $14.88 · 2025-02-20 to 2034-03-05 | 27,338 Common Stock | (F2) 25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims. |